This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
EMN vs. AIQUY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EMN vs. AIQUY: Which Stock Is the Better Value Option?
Are Investors Undervaluing Eastman Chemical (EMN) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Eastman (EMN) in Your Portfolio
by Zacks Equity Research
Eastman (EMN) will gain from cost-cutting and productivity actions, synergies of strategic acquisitions and sustained innovation. However, it is expected to face headwinds from unfavorable currency translations.
Celanese (CE) & Mitsui Ink New Partnership, Extend Fairway JV
by Zacks Equity Research
Celanese (CE) joins forces with Mitsui to form a new Food Ingredient joint venture to strengthen its strategic partnership with the latter.
Century Casinos and Eastman Chemical have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Century Casinos and Eastman Chemical have been highlighted as Zacks Bull and Bear of the Day.
Bear of the Day: Eastman Chemical (EMN)
by David Bartosiak
Chemical stocks had their day in the sun, are earnings saying the best is over?
Eastman Chemical's (EMN) Q4 Earnings Lag Estimates, Sales Beat
by Zacks Equity Research
Eastman Chemical's (EMN) Q4 performance reflects headwinds from weak demand in key end markets, consumer de-stocking and input cost inflation, along with impacts from adverse currency movements.
Eastman Chemical (EMN) Misses Q4 Earnings Estimates
by Zacks Equity Research
Eastman Chemical (EMN) delivered earnings and revenue surprises of -29.37% and 3.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Chemical Stock Q4 Earnings Slated on Jan 26: DOW, EMN & OLN
by Anindya Barman
Chemical companies' Q4 results are likely to have been driven by stable end-market demand and the benefits of strategic actions amid headwinds from input and energy cost inflation. Let's see how DOW, EMN and OLN are poised ahead of their earnings releases.
Eastman Chemical (EMN) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Eastman Chemical's (EMN) earnings are expected to have gained from sustained innovation & recovery in key end markets amid headwinds from adverse currency movements & consumer de-stocking in Q4.
Earnings Preview: LyondellBasell (LYB) Q4 Earnings Expected to Decline
by Zacks Equity Research
LyondellBasell (LYB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Eastman Chemical (EMN) Q4 Earnings Expected to Decline
by Zacks Equity Research
Eastman Chemical (EMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Cabot (CBT) Up 2% Since Last Earnings Report?
by Zacks Equity Research
Cabot (CBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kronos Worldwide (KRO) Up 3.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Kronos Worldwide (KRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is FMC (FMC) Up 9% Since Last Earnings Report?
by Zacks Equity Research
FMC (FMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Eastman Chemical's (EMN) Q3 Earnings & Sales Top Estimates
by Zacks Equity Research
Eastman Chemical (EMN) benefits from actions to improve mix with innovative products and implement price hikes to counter cost inflation in Q3.
Eastman Chemical (EMN) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Eastman Chemical (EMN) delivered earnings and revenue surprises of 2.50% and 5.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Methanex (MEOH) Misses Q3 Earnings Estimates
by Zacks Equity Research
Methanex (MEOH) delivered earnings and revenue surprises of -15.85% and 3.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: FMC (FMC) Q3 Earnings Expected to Decline
by Zacks Equity Research
FMC (FMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eastman Chemical (EMN) to Post Q3 Earnings: Factors at Play
by Zacks Equity Research
Eastman Chemical (EMN) is likely to have gained from pricing and cost actions amid headwinds from higher raw material, energy and distribution costs in Q3.
Albemarle (ALB) Gains on Strong Demand, Capacity Expansion
by Zacks Equity Research
Albemarle (ALB) rides on strong demand and prices in its lithium and bromine businesses.
Analysts Estimate Eastman Chemical (EMN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Eastman Chemical (EMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stepan Co. (SCL) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Stepan Co. (SCL) delivered earnings and revenue surprises of 24.84% and 8.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Eastman Chemical (EMN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Eastman Chemical (EMN) stock based on the movements in the options market lately.
Here's Why You Should Hold Eastman Chemical (EMN) for Now
by Zacks Equity Research
While Eastman Chemical (EMN) faces headwinds from higher input and logistics costs, it benefits from productivity actions, strong demand and innovation.